VIR-3434
Chronic Hepatitis B
Preclinical/Phase 1 (ex-China)Option Exercised
Key Facts
Indication
Chronic Hepatitis B
Phase
Preclinical/Phase 1 (ex-China)
Status
Option Exercised
Company
About Brii Biosciences
Founded in 2018, Brii Biosciences is a publicly traded biotech with a mission to address major public health challenges in infectious diseases and CNS disorders. Its core strategy involves in-licensing and co-developing clinical-stage assets, most notably achieving the first NMPA-approved COVID-19 neutralizing antibody combination in China. The company operates with a dual-US/China footprint, aiming to accelerate global innovation for patients in high-need markets.
View full company profileTherapeutic Areas
Other Chronic Hepatitis B Drugs
| Drug | Company | Phase |
|---|---|---|
| Selgantolimod (GS-9688) | Gilead | Phase 2 |
| Bepirovirsen | GSK | Phase III |
| BRII-835 (VIR-2218) + BRII-179 (VBI-2601) | Brii Biosciences | Phase 2 |
| BRII-179 (VBI-2601) | Brii Biosciences | Phase 2a/2b |
| JNJ-3989 | Johnson & Johnson | Phase 2 |
| APG-1387 | Ascentage Pharma Group | Phase 2 |
| VTP-300 | Barinthus Biotherapeutics | Phase 1b/2a |